The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Fremanezumab—A Humanized Monoclonal Anti-CGRP Antibody—Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors
Open accessAbstract
Calcitonin gene-related peptide (CGRP), the most abundant neuropeptide in primary afferent sensory neurons, is strongly implicated in the pathophysiology of migraine headache, but its role in migraine is still equivocal. As a new approach to migraine treatment, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs) were developed to reduce the availability of CGRP, and were found effective in reducing the frequency of chronic and episodic migraine. We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons. To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats. Fremanezumab pretreatment selectively inhibited the responsiveness of Aδ neurons, but not C-fiber neurons, as reflected in a decrease in the percentage of neurons that showed activation by cortical spreading depression. These findings identify Aδ meningeal nociceptors as a likely site of action of fremanezumab in the prevention of headache. The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-δ input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients. SIGNIFICANCE STATEMENT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and sensitization of high-threshold (HT) but not wide-dynamic range trigeminovascular neurons by cortical spreading depression (CSD). In the current paper, we report that CGRP-mAbs prevent the activation of Aδ but not C-type meningeal nociceptors by CSD. This is the first identification of an anti-migraine drug that appears to be selective for Aδ-fibers (peripherally) and HT neurons (centrally). As the main CGRP-mAb site of action appears to be situated outside the brain, we conclude that the initiation of the headache phase of migraine depends on activation of meningeal nociceptors, and that for selected patients, activation of the Aδ-HT pain pathway may be sufficient for the generation of headache perception.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spreading Depression, Spreading Depolarizations, and the Cerebral Vasculature
Ayata, C., & Lauritzen, M. (2015) · Physiological Reviews · doi:10.1152/physrev.00027.2014 · Cited by 555
Cited by
Migraine and the trigeminovascular system—40 years and counting
Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz, M. A. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30185-1 · Cited by 606
Self-citationDodick, D. W. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30478-1 · Cited by 557
CGRP and the Trigeminal System in Migraine
Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13529 · Cited by 486
Current understanding of osteoarthritis pathogenesis and relevant new approaches
Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., Wang, H., Xing, L., & Chen, D. (2022) · Bone Research · doi:10.1038/s41413-022-00226-9 · Cited by 437
Does inflammation have a role in migraine?
Edvinsson, L., Haanes, K. A., & Warfvinge, K. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0216-y · Cited by 311
Metadata
- Authors
- Melo-Carrillo, A., Strassman, A. M., Nir, R.-R., Schain, A. J., Noseda, R., Stratton, J., & Burstein, R.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-09-29
- Volume
- 37
- Issue
- 44
- Pages
- 10587-10596
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2760684802
- Cited by
- 189
- References
- 1
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fremanezumab—A Humanized Monoclonal Anti-CGRP Antibody—Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. https://app.cochat.ai/papers/10.1523/jneurosci.2211-17.2017
- The paper
- Melo-Carrillo, A., Strassman, A. M., Nir, R.-R., Schain, A. J., Noseda, R., Stratton, J., & Burstein, R. (2017). Fremanezumab—A Humanized Monoclonal Anti-CGRP Antibody—Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.2211-17.2017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.